nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—ABCG2—Sulfasalazine—ankylosing spondylitis	0.0942	0.223	CbGbCtD
Vandetanib—ABCC1—Methotrexate—ankylosing spondylitis	0.0564	0.134	CbGbCtD
Vandetanib—ALB—Prednisone—ankylosing spondylitis	0.0519	0.123	CbGbCtD
Vandetanib—ABCG2—Dexamethasone—ankylosing spondylitis	0.047	0.111	CbGbCtD
Vandetanib—ABCG2—Methotrexate—ankylosing spondylitis	0.0378	0.0896	CbGbCtD
Vandetanib—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0268	0.0637	CbGbCtD
Vandetanib—ALB—Methotrexate—ankylosing spondylitis	0.026	0.0617	CbGbCtD
Vandetanib—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0203	0.0483	CbGbCtD
Vandetanib—CYP3A4—Betamethasone—ankylosing spondylitis	0.0175	0.0414	CbGbCtD
Vandetanib—CYP3A4—Prednisolone—ankylosing spondylitis	0.0172	0.0408	CbGbCtD
Vandetanib—CYP3A4—Prednisone—ankylosing spondylitis	0.0163	0.0386	CbGbCtD
Vandetanib—CYP3A4—Dexamethasone—ankylosing spondylitis	0.0102	0.0241	CbGbCtD
Vandetanib—RIPK2—synovial membrane of synovial joint—ankylosing spondylitis	0.00757	0.241	CbGeAlD
Vandetanib—ORM1—vertebral column—ankylosing spondylitis	0.00425	0.135	CbGeAlD
Vandetanib—STK35—tendon—ankylosing spondylitis	0.00124	0.0395	CbGeAlD
Vandetanib—ABL2—tendon—ankylosing spondylitis	0.00121	0.0385	CbGeAlD
Vandetanib—RIPK2—tendon—ankylosing spondylitis	0.00114	0.0365	CbGeAlD
Vandetanib—VEGFA—tendon—ankylosing spondylitis	0.00114	0.0364	CbGeAlD
Vandetanib—FMO1—tendon—ankylosing spondylitis	0.00114	0.0362	CbGeAlD
Vandetanib—IRAK4—tendon—ankylosing spondylitis	0.00112	0.0356	CbGeAlD
Vandetanib—FGR—tendon—ankylosing spondylitis	0.00102	0.0324	CbGeAlD
Vandetanib—RET—tendon—ankylosing spondylitis	0.00102	0.0324	CbGeAlD
Vandetanib—AXL—tendon—ankylosing spondylitis	0.00101	0.0322	CbGeAlD
Vandetanib—SLK—tendon—ankylosing spondylitis	0.000974	0.031	CbGeAlD
Vandetanib—FYN—tendon—ankylosing spondylitis	0.000947	0.0302	CbGeAlD
Vandetanib—TEK—tendon—ankylosing spondylitis	0.000926	0.0295	CbGeAlD
Vandetanib—MAP4K5—tendon—ankylosing spondylitis	0.000926	0.0295	CbGeAlD
Vandetanib—EPHB6—tendon—ankylosing spondylitis	0.000885	0.0282	CbGeAlD
Vandetanib—YES1—tendon—ankylosing spondylitis	0.000855	0.0272	CbGeAlD
Vandetanib—STK10—tendon—ankylosing spondylitis	0.000847	0.027	CbGeAlD
Vandetanib—VEGFA—Dexamethasone—Methylprednisolone—ankylosing spondylitis	0.000757	0.105	CbGdCrCtD
Vandetanib—VEGFA—Betamethasone—Methylprednisolone—ankylosing spondylitis	0.000757	0.105	CbGdCrCtD
Vandetanib—KDR—tendon—ankylosing spondylitis	0.000757	0.0241	CbGeAlD
Vandetanib—MAP2K5—tendon—ankylosing spondylitis	0.000757	0.0241	CbGeAlD
Vandetanib—VEGFA—Dexamethasone—Betamethasone—ankylosing spondylitis	0.000745	0.104	CbGdCrCtD
Vandetanib—VEGFA—Betamethasone—Dexamethasone—ankylosing spondylitis	0.000745	0.104	CbGdCrCtD
Vandetanib—VEGFA—Betamethasone—Triamcinolone—ankylosing spondylitis	0.000728	0.101	CbGdCrCtD
Vandetanib—VEGFA—Dexamethasone—Triamcinolone—ankylosing spondylitis	0.000728	0.101	CbGdCrCtD
Vandetanib—VEGFA—Dexamethasone—Prednisone—ankylosing spondylitis	0.000691	0.0961	CbGdCrCtD
Vandetanib—VEGFA—Betamethasone—Prednisone—ankylosing spondylitis	0.000691	0.0961	CbGdCrCtD
Vandetanib—VEGFA—Dexamethasone—Prednisolone—ankylosing spondylitis	0.000674	0.0938	CbGdCrCtD
Vandetanib—VEGFA—Betamethasone—Prednisolone—ankylosing spondylitis	0.000674	0.0938	CbGdCrCtD
Vandetanib—PDGFRB—tendon—ankylosing spondylitis	0.000655	0.0209	CbGeAlD
Vandetanib—ABL1—tendon—ankylosing spondylitis	0.000584	0.0186	CbGeAlD
Vandetanib—Lethargy—Methotrexate—ankylosing spondylitis	0.000556	0.00218	CcSEcCtD
Vandetanib—Arrhythmia—Prednisolone—ankylosing spondylitis	0.000554	0.00217	CcSEcCtD
Vandetanib—Pancreatitis—Prednisone—ankylosing spondylitis	0.000552	0.00217	CcSEcCtD
Vandetanib—Visual impairment—Methylprednisolone—ankylosing spondylitis	0.000548	0.00215	CcSEcCtD
Vandetanib—Eye disorder—Methylprednisolone—ankylosing spondylitis	0.000532	0.00209	CcSEcCtD
Vandetanib—Cardiac disorder—Methylprednisolone—ankylosing spondylitis	0.000528	0.00207	CcSEcCtD
Vandetanib—Bradycardia—Dexamethasone—ankylosing spondylitis	0.000527	0.00207	CcSEcCtD
Vandetanib—Bradycardia—Betamethasone—ankylosing spondylitis	0.000527	0.00207	CcSEcCtD
Vandetanib—Neutropenia—Prednisone—ankylosing spondylitis	0.000527	0.00207	CcSEcCtD
Vandetanib—Haemoglobin—Dexamethasone—ankylosing spondylitis	0.00052	0.00204	CcSEcCtD
Vandetanib—Haemoglobin—Betamethasone—ankylosing spondylitis	0.00052	0.00204	CcSEcCtD
Vandetanib—Haemorrhage—Betamethasone—ankylosing spondylitis	0.000518	0.00203	CcSEcCtD
Vandetanib—Haemorrhage—Dexamethasone—ankylosing spondylitis	0.000518	0.00203	CcSEcCtD
Vandetanib—Angiopathy—Methylprednisolone—ankylosing spondylitis	0.000516	0.00203	CcSEcCtD
Vandetanib—Mediastinal disorder—Methylprednisolone—ankylosing spondylitis	0.000513	0.00201	CcSEcCtD
Vandetanib—Arrhythmia—Triamcinolone—ankylosing spondylitis	0.00051	0.002	CcSEcCtD
Vandetanib—Weight decreased—Prednisone—ankylosing spondylitis	0.000509	0.002	CcSEcCtD
Vandetanib—Vision blurred—Prednisolone—ankylosing spondylitis	0.000509	0.002	CcSEcCtD
Vandetanib—Arrhythmia—Methylprednisolone—ankylosing spondylitis	0.000508	0.002	CcSEcCtD
Vandetanib—Hyperglycaemia—Prednisone—ankylosing spondylitis	0.000508	0.00199	CcSEcCtD
Vandetanib—Depression—Prednisone—ankylosing spondylitis	0.000501	0.00196	CcSEcCtD
Vandetanib—Visual impairment—Betamethasone—ankylosing spondylitis	0.000499	0.00196	CcSEcCtD
Vandetanib—Visual impairment—Dexamethasone—ankylosing spondylitis	0.000499	0.00196	CcSEcCtD
Vandetanib—Mental disorder—Methylprednisolone—ankylosing spondylitis	0.000499	0.00196	CcSEcCtD
Vandetanib—Malnutrition—Methylprednisolone—ankylosing spondylitis	0.000495	0.00194	CcSEcCtD
Vandetanib—Dysgeusia—Triamcinolone—ankylosing spondylitis	0.000486	0.00191	CcSEcCtD
Vandetanib—Eye disorder—Dexamethasone—ankylosing spondylitis	0.000484	0.0019	CcSEcCtD
Vandetanib—Eye disorder—Betamethasone—ankylosing spondylitis	0.000484	0.0019	CcSEcCtD
Vandetanib—Loss of consciousness—Prednisolone—ankylosing spondylitis	0.000475	0.00186	CcSEcCtD
Vandetanib—Angiopathy—Betamethasone—ankylosing spondylitis	0.00047	0.00184	CcSEcCtD
Vandetanib—Angiopathy—Dexamethasone—ankylosing spondylitis	0.00047	0.00184	CcSEcCtD
Vandetanib—Convulsion—Prednisolone—ankylosing spondylitis	0.000468	0.00184	CcSEcCtD
Vandetanib—Hypertension—Prednisolone—ankylosing spondylitis	0.000466	0.00183	CcSEcCtD
Vandetanib—Arrhythmia—Dexamethasone—ankylosing spondylitis	0.000462	0.00181	CcSEcCtD
Vandetanib—Arrhythmia—Betamethasone—ankylosing spondylitis	0.000462	0.00181	CcSEcCtD
Vandetanib—Pancreatitis—Methotrexate—ankylosing spondylitis	0.000461	0.00181	CcSEcCtD
Vandetanib—Bradycardia—Prednisone—ankylosing spondylitis	0.000459	0.0018	CcSEcCtD
Vandetanib—Alopecia—Dexamethasone—ankylosing spondylitis	0.000457	0.00179	CcSEcCtD
Vandetanib—Alopecia—Betamethasone—ankylosing spondylitis	0.000457	0.00179	CcSEcCtD
Vandetanib—Haemoglobin—Prednisone—ankylosing spondylitis	0.000453	0.00178	CcSEcCtD
Vandetanib—Haemorrhage—Prednisone—ankylosing spondylitis	0.000451	0.00177	CcSEcCtD
Vandetanib—ABCC1—tendon—ankylosing spondylitis	0.000445	0.0142	CbGeAlD
Vandetanib—Oedema—Prednisolone—ankylosing spondylitis	0.000441	0.00173	CcSEcCtD
Vandetanib—Dysuria—Methotrexate—ankylosing spondylitis	0.00044	0.00173	CcSEcCtD
Vandetanib—Neutropenia—Methotrexate—ankylosing spondylitis	0.00044	0.00173	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Methotrexate—ankylosing spondylitis	0.000437	0.00172	CcSEcCtD
Vandetanib—Loss of consciousness—Triamcinolone—ankylosing spondylitis	0.000436	0.00171	CcSEcCtD
Vandetanib—Loss of consciousness—Methylprednisolone—ankylosing spondylitis	0.000435	0.00171	CcSEcCtD
Vandetanib—Cough—Triamcinolone—ankylosing spondylitis	0.000433	0.0017	CcSEcCtD
Vandetanib—Convulsion—Triamcinolone—ankylosing spondylitis	0.00043	0.00169	CcSEcCtD
Vandetanib—Photosensitivity reaction—Methotrexate—ankylosing spondylitis	0.00043	0.00169	CcSEcCtD
Vandetanib—Convulsion—Methylprednisolone—ankylosing spondylitis	0.000429	0.00168	CcSEcCtD
Vandetanib—Hypertension—Triamcinolone—ankylosing spondylitis	0.000429	0.00168	CcSEcCtD
Vandetanib—Hypertension—Methylprednisolone—ankylosing spondylitis	0.000428	0.00168	CcSEcCtD
Vandetanib—Pneumonia—Methotrexate—ankylosing spondylitis	0.000422	0.00166	CcSEcCtD
Vandetanib—Arthralgia—Methylprednisolone—ankylosing spondylitis	0.000422	0.00166	CcSEcCtD
Vandetanib—Eye disorder—Prednisone—ankylosing spondylitis	0.000421	0.00165	CcSEcCtD
Vandetanib—Anxiety—Methylprednisolone—ankylosing spondylitis	0.00042	0.00165	CcSEcCtD
Vandetanib—Infestation NOS—Methotrexate—ankylosing spondylitis	0.00042	0.00165	CcSEcCtD
Vandetanib—Infestation—Methotrexate—ankylosing spondylitis	0.00042	0.00165	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000419	0.00164	CcSEcCtD
Vandetanib—Depression—Methotrexate—ankylosing spondylitis	0.000418	0.00164	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Methotrexate—ankylosing spondylitis	0.000416	0.00163	CcSEcCtD
Vandetanib—Dry mouth—Triamcinolone—ankylosing spondylitis	0.000413	0.00162	CcSEcCtD
Vandetanib—Renal failure—Methotrexate—ankylosing spondylitis	0.000412	0.00162	CcSEcCtD
Vandetanib—Stomatitis—Methotrexate—ankylosing spondylitis	0.000409	0.00161	CcSEcCtD
Vandetanib—Angiopathy—Prednisone—ankylosing spondylitis	0.000409	0.0016	CcSEcCtD
Vandetanib—Conjunctivitis—Methotrexate—ankylosing spondylitis	0.000408	0.0016	CcSEcCtD
Vandetanib—Oedema—Triamcinolone—ankylosing spondylitis	0.000405	0.00159	CcSEcCtD
Vandetanib—Arrhythmia—Prednisone—ankylosing spondylitis	0.000403	0.00158	CcSEcCtD
Vandetanib—Infection—Triamcinolone—ankylosing spondylitis	0.000403	0.00158	CcSEcCtD
Vandetanib—Infection—Methylprednisolone—ankylosing spondylitis	0.000402	0.00158	CcSEcCtD
Vandetanib—Haematuria—Methotrexate—ankylosing spondylitis	0.0004	0.00157	CcSEcCtD
Vandetanib—Insomnia—Prednisolone—ankylosing spondylitis	0.000399	0.00156	CcSEcCtD
Vandetanib—Alopecia—Prednisone—ankylosing spondylitis	0.000398	0.00156	CcSEcCtD
Vandetanib—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.000397	0.00156	CcSEcCtD
Vandetanib—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000397	0.00156	CcSEcCtD
Vandetanib—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.000396	0.00155	CcSEcCtD
Vandetanib—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.000396	0.00155	CcSEcCtD
Vandetanib—Epistaxis—Methotrexate—ankylosing spondylitis	0.000396	0.00155	CcSEcCtD
Vandetanib—Paraesthesia—Prednisolone—ankylosing spondylitis	0.000396	0.00155	CcSEcCtD
Vandetanib—Mental disorder—Prednisone—ankylosing spondylitis	0.000395	0.00155	CcSEcCtD
Vandetanib—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000393	0.00154	CcSEcCtD
Vandetanib—Malnutrition—Prednisone—ankylosing spondylitis	0.000392	0.00154	CcSEcCtD
Vandetanib—Convulsion—Betamethasone—ankylosing spondylitis	0.00039	0.00153	CcSEcCtD
Vandetanib—Convulsion—Dexamethasone—ankylosing spondylitis	0.00039	0.00153	CcSEcCtD
Vandetanib—Hypertension—Dexamethasone—ankylosing spondylitis	0.000389	0.00153	CcSEcCtD
Vandetanib—Hypertension—Betamethasone—ankylosing spondylitis	0.000389	0.00153	CcSEcCtD
Vandetanib—Anxiety—Dexamethasone—ankylosing spondylitis	0.000382	0.0015	CcSEcCtD
Vandetanib—Anxiety—Betamethasone—ankylosing spondylitis	0.000382	0.0015	CcSEcCtD
Vandetanib—Haemoglobin—Methotrexate—ankylosing spondylitis	0.000379	0.00149	CcSEcCtD
Vandetanib—Pain—Prednisolone—ankylosing spondylitis	0.000377	0.00148	CcSEcCtD
Vandetanib—Haemorrhage—Methotrexate—ankylosing spondylitis	0.000377	0.00148	CcSEcCtD
Vandetanib—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.000372	0.00146	CcSEcCtD
Vandetanib—Vision blurred—Prednisone—ankylosing spondylitis	0.00037	0.00145	CcSEcCtD
Vandetanib—Urethral disorder—Methotrexate—ankylosing spondylitis	0.000369	0.00145	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.000369	0.00145	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000368	0.00145	CcSEcCtD
Vandetanib—Oedema—Dexamethasone—ankylosing spondylitis	0.000368	0.00144	CcSEcCtD
Vandetanib—Oedema—Betamethasone—ankylosing spondylitis	0.000368	0.00144	CcSEcCtD
Vandetanib—Insomnia—Triamcinolone—ankylosing spondylitis	0.000367	0.00144	CcSEcCtD
Vandetanib—Insomnia—Methylprednisolone—ankylosing spondylitis	0.000366	0.00144	CcSEcCtD
Vandetanib—Infection—Dexamethasone—ankylosing spondylitis	0.000365	0.00143	CcSEcCtD
Vandetanib—Infection—Betamethasone—ankylosing spondylitis	0.000365	0.00143	CcSEcCtD
Vandetanib—Paraesthesia—Triamcinolone—ankylosing spondylitis	0.000364	0.00143	CcSEcCtD
Vandetanib—Paraesthesia—Methylprednisolone—ankylosing spondylitis	0.000363	0.00142	CcSEcCtD
Vandetanib—Visual impairment—Methotrexate—ankylosing spondylitis	0.000363	0.00142	CcSEcCtD
Vandetanib—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.000361	0.00142	CcSEcCtD
Vandetanib—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000361	0.00142	CcSEcCtD
Vandetanib—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000361	0.00142	CcSEcCtD
Vandetanib—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.00036	0.00141	CcSEcCtD
Vandetanib—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.00036	0.00141	CcSEcCtD
Vandetanib—Dyspepsia—Triamcinolone—ankylosing spondylitis	0.000357	0.0014	CcSEcCtD
Vandetanib—Erythema multiforme—Methotrexate—ankylosing spondylitis	0.000356	0.0014	CcSEcCtD
Vandetanib—Dyspepsia—Methylprednisolone—ankylosing spondylitis	0.000356	0.0014	CcSEcCtD
Vandetanib—Eye disorder—Methotrexate—ankylosing spondylitis	0.000352	0.00138	CcSEcCtD
Vandetanib—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.00035	0.00137	CcSEcCtD
Vandetanib—Fatigue—Triamcinolone—ankylosing spondylitis	0.000349	0.00137	CcSEcCtD
Vandetanib—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000349	0.00137	CcSEcCtD
Vandetanib—Pain—Triamcinolone—ankylosing spondylitis	0.000347	0.00136	CcSEcCtD
Vandetanib—Loss of consciousness—Prednisone—ankylosing spondylitis	0.000345	0.00135	CcSEcCtD
Vandetanib—Angiopathy—Methotrexate—ankylosing spondylitis	0.000342	0.00134	CcSEcCtD
Vandetanib—Convulsion—Prednisone—ankylosing spondylitis	0.00034	0.00133	CcSEcCtD
Vandetanib—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.000339	0.00133	CcSEcCtD
Vandetanib—Hypertension—Prednisone—ankylosing spondylitis	0.000339	0.00133	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.000335	0.00131	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.000335	0.00131	CcSEcCtD
Vandetanib—Arthralgia—Prednisone—ankylosing spondylitis	0.000334	0.00131	CcSEcCtD
Vandetanib—Anxiety—Prednisone—ankylosing spondylitis	0.000333	0.00131	CcSEcCtD
Vandetanib—Alopecia—Methotrexate—ankylosing spondylitis	0.000333	0.00131	CcSEcCtD
Vandetanib—Insomnia—Dexamethasone—ankylosing spondylitis	0.000333	0.00131	CcSEcCtD
Vandetanib—Insomnia—Betamethasone—ankylosing spondylitis	0.000333	0.00131	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000332	0.0013	CcSEcCtD
Vandetanib—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.000331	0.0013	CcSEcCtD
Vandetanib—Paraesthesia—Betamethasone—ankylosing spondylitis	0.00033	0.0013	CcSEcCtD
Vandetanib—Paraesthesia—Dexamethasone—ankylosing spondylitis	0.00033	0.0013	CcSEcCtD
Vandetanib—Mental disorder—Methotrexate—ankylosing spondylitis	0.00033	0.0013	CcSEcCtD
Vandetanib—Malnutrition—Methotrexate—ankylosing spondylitis	0.000328	0.00129	CcSEcCtD
Vandetanib—Dyspepsia—Betamethasone—ankylosing spondylitis	0.000324	0.00127	CcSEcCtD
Vandetanib—Dyspepsia—Dexamethasone—ankylosing spondylitis	0.000324	0.00127	CcSEcCtD
Vandetanib—Dysgeusia—Methotrexate—ankylosing spondylitis	0.000321	0.00126	CcSEcCtD
Vandetanib—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.00032	0.00126	CcSEcCtD
Vandetanib—Oedema—Prednisone—ankylosing spondylitis	0.00032	0.00126	CcSEcCtD
Vandetanib—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.00032	0.00125	CcSEcCtD
Vandetanib—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.00032	0.00125	CcSEcCtD
Vandetanib—Decreased appetite—Betamethasone—ankylosing spondylitis	0.00032	0.00125	CcSEcCtD
Vandetanib—Infection—Prednisone—ankylosing spondylitis	0.000318	0.00125	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000317	0.00125	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000317	0.00125	CcSEcCtD
Vandetanib—Fatigue—Dexamethasone—ankylosing spondylitis	0.000317	0.00124	CcSEcCtD
Vandetanib—Fatigue—Betamethasone—ankylosing spondylitis	0.000317	0.00124	CcSEcCtD
Vandetanib—Pain—Dexamethasone—ankylosing spondylitis	0.000314	0.00123	CcSEcCtD
Vandetanib—Pain—Betamethasone—ankylosing spondylitis	0.000314	0.00123	CcSEcCtD
Vandetanib—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000314	0.00123	CcSEcCtD
Vandetanib—Skin disorder—Prednisone—ankylosing spondylitis	0.000311	0.00122	CcSEcCtD
Vandetanib—Vision blurred—Methotrexate—ankylosing spondylitis	0.000309	0.00121	CcSEcCtD
Vandetanib—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.000301	0.00118	CcSEcCtD
Vandetanib—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.000301	0.00118	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.000292	0.00114	CcSEcCtD
Vandetanib—Dizziness—Prednisolone—ankylosing spondylitis	0.000291	0.00114	CcSEcCtD
Vandetanib—Asthenia—Triamcinolone—ankylosing spondylitis	0.000291	0.00114	CcSEcCtD
Vandetanib—Abdominal pain—Betamethasone—ankylosing spondylitis	0.000291	0.00114	CcSEcCtD
Vandetanib—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.000291	0.00114	CcSEcCtD
Vandetanib—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.000291	0.00114	CcSEcCtD
Vandetanib—Body temperature increased—Betamethasone—ankylosing spondylitis	0.000291	0.00114	CcSEcCtD
Vandetanib—Asthenia—Methylprednisolone—ankylosing spondylitis	0.00029	0.00114	CcSEcCtD
Vandetanib—Insomnia—Prednisone—ankylosing spondylitis	0.00029	0.00114	CcSEcCtD
Vandetanib—Paraesthesia—Prednisone—ankylosing spondylitis	0.000288	0.00113	CcSEcCtD
Vandetanib—Pruritus—Triamcinolone—ankylosing spondylitis	0.000287	0.00113	CcSEcCtD
Vandetanib—Cough—Methotrexate—ankylosing spondylitis	0.000286	0.00112	CcSEcCtD
Vandetanib—Pruritus—Methylprednisolone—ankylosing spondylitis	0.000286	0.00112	CcSEcCtD
Vandetanib—Convulsion—Methotrexate—ankylosing spondylitis	0.000284	0.00111	CcSEcCtD
Vandetanib—Dyspepsia—Prednisone—ankylosing spondylitis	0.000282	0.00111	CcSEcCtD
Vandetanib—Arthralgia—Methotrexate—ankylosing spondylitis	0.000279	0.0011	CcSEcCtD
Vandetanib—Chest pain—Methotrexate—ankylosing spondylitis	0.000279	0.0011	CcSEcCtD
Vandetanib—Decreased appetite—Prednisone—ankylosing spondylitis	0.000278	0.00109	CcSEcCtD
Vandetanib—Rash—Prednisolone—ankylosing spondylitis	0.000278	0.00109	CcSEcCtD
Vandetanib—Dermatitis—Prednisolone—ankylosing spondylitis	0.000278	0.00109	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000277	0.00109	CcSEcCtD
Vandetanib—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.000277	0.00109	CcSEcCtD
Vandetanib—Fatigue—Prednisone—ankylosing spondylitis	0.000276	0.00108	CcSEcCtD
Vandetanib—Headache—Prednisolone—ankylosing spondylitis	0.000276	0.00108	CcSEcCtD
Vandetanib—Constipation—Prednisone—ankylosing spondylitis	0.000274	0.00107	CcSEcCtD
Vandetanib—Dizziness—Triamcinolone—ankylosing spondylitis	0.000268	0.00105	CcSEcCtD
Vandetanib—Dizziness—Methylprednisolone—ankylosing spondylitis	0.000267	0.00105	CcSEcCtD
Vandetanib—Infection—Methotrexate—ankylosing spondylitis	0.000266	0.00104	CcSEcCtD
Vandetanib—Asthenia—Betamethasone—ankylosing spondylitis	0.000264	0.00104	CcSEcCtD
Vandetanib—Asthenia—Dexamethasone—ankylosing spondylitis	0.000264	0.00104	CcSEcCtD
Vandetanib—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.000262	0.00103	CcSEcCtD
Vandetanib—Thrombocytopenia—Methotrexate—ankylosing spondylitis	0.000262	0.00103	CcSEcCtD
Vandetanib—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.000262	0.00103	CcSEcCtD
Vandetanib—Nausea—Prednisolone—ankylosing spondylitis	0.000262	0.00103	CcSEcCtD
Vandetanib—Pruritus—Betamethasone—ankylosing spondylitis	0.00026	0.00102	CcSEcCtD
Vandetanib—Pruritus—Dexamethasone—ankylosing spondylitis	0.00026	0.00102	CcSEcCtD
Vandetanib—Skin disorder—Methotrexate—ankylosing spondylitis	0.00026	0.00102	CcSEcCtD
Vandetanib—Vomiting—Triamcinolone—ankylosing spondylitis	0.000258	0.00101	CcSEcCtD
Vandetanib—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000257	0.00101	CcSEcCtD
Vandetanib—Rash—Triamcinolone—ankylosing spondylitis	0.000256	0.001	CcSEcCtD
Vandetanib—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000255	0.001	CcSEcCtD
Vandetanib—Rash—Methylprednisolone—ankylosing spondylitis	0.000255	0.001	CcSEcCtD
Vandetanib—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000255	0.001	CcSEcCtD
Vandetanib—Headache—Triamcinolone—ankylosing spondylitis	0.000254	0.000996	CcSEcCtD
Vandetanib—Headache—Methylprednisolone—ankylosing spondylitis	0.000253	0.000994	CcSEcCtD
Vandetanib—Abdominal pain—Prednisone—ankylosing spondylitis	0.000253	0.000993	CcSEcCtD
Vandetanib—Body temperature increased—Prednisone—ankylosing spondylitis	0.000253	0.000993	CcSEcCtD
Vandetanib—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000252	0.000987	CcSEcCtD
Vandetanib—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000252	0.000987	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.000244	0.000957	CcSEcCtD
Vandetanib—Dizziness—Betamethasone—ankylosing spondylitis	0.000243	0.000954	CcSEcCtD
Vandetanib—Dizziness—Dexamethasone—ankylosing spondylitis	0.000243	0.000954	CcSEcCtD
Vandetanib—Insomnia—Methotrexate—ankylosing spondylitis	0.000242	0.00095	CcSEcCtD
Vandetanib—Nausea—Triamcinolone—ankylosing spondylitis	0.000241	0.000945	CcSEcCtD
Vandetanib—Paraesthesia—Methotrexate—ankylosing spondylitis	0.00024	0.000943	CcSEcCtD
Vandetanib—Nausea—Methylprednisolone—ankylosing spondylitis	0.00024	0.000943	CcSEcCtD
Vandetanib—Dyspnoea—Methotrexate—ankylosing spondylitis	0.000239	0.000936	CcSEcCtD
Vandetanib—Dyspepsia—Methotrexate—ankylosing spondylitis	0.000236	0.000924	CcSEcCtD
Vandetanib—Vomiting—Dexamethasone—ankylosing spondylitis	0.000234	0.000917	CcSEcCtD
Vandetanib—Vomiting—Betamethasone—ankylosing spondylitis	0.000234	0.000917	CcSEcCtD
Vandetanib—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000233	0.000913	CcSEcCtD
Vandetanib—Rash—Dexamethasone—ankylosing spondylitis	0.000232	0.00091	CcSEcCtD
Vandetanib—Rash—Betamethasone—ankylosing spondylitis	0.000232	0.00091	CcSEcCtD
Vandetanib—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000232	0.000909	CcSEcCtD
Vandetanib—Dermatitis—Betamethasone—ankylosing spondylitis	0.000232	0.000909	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000231	0.000907	CcSEcCtD
Vandetanib—Fatigue—Methotrexate—ankylosing spondylitis	0.000231	0.000905	CcSEcCtD
Vandetanib—Headache—Dexamethasone—ankylosing spondylitis	0.00023	0.000904	CcSEcCtD
Vandetanib—Headache—Betamethasone—ankylosing spondylitis	0.00023	0.000904	CcSEcCtD
Vandetanib—Asthenia—Prednisone—ankylosing spondylitis	0.00023	0.000902	CcSEcCtD
Vandetanib—Pain—Methotrexate—ankylosing spondylitis	0.000229	0.000898	CcSEcCtD
Vandetanib—Pruritus—Prednisone—ankylosing spondylitis	0.000227	0.000889	CcSEcCtD
Vandetanib—Diarrhoea—Prednisone—ankylosing spondylitis	0.000219	0.00086	CcSEcCtD
Vandetanib—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.000219	0.000859	CcSEcCtD
Vandetanib—Nausea—Dexamethasone—ankylosing spondylitis	0.000218	0.000857	CcSEcCtD
Vandetanib—Nausea—Betamethasone—ankylosing spondylitis	0.000218	0.000857	CcSEcCtD
Vandetanib—Dizziness—Prednisone—ankylosing spondylitis	0.000212	0.000831	CcSEcCtD
Vandetanib—Abdominal pain—Methotrexate—ankylosing spondylitis	0.000212	0.00083	CcSEcCtD
Vandetanib—Body temperature increased—Methotrexate—ankylosing spondylitis	0.000212	0.00083	CcSEcCtD
Vandetanib—Vomiting—Prednisone—ankylosing spondylitis	0.000204	0.000799	CcSEcCtD
Vandetanib—Rash—Prednisone—ankylosing spondylitis	0.000202	0.000792	CcSEcCtD
Vandetanib—Dermatitis—Prednisone—ankylosing spondylitis	0.000202	0.000792	CcSEcCtD
Vandetanib—Headache—Prednisone—ankylosing spondylitis	0.000201	0.000787	CcSEcCtD
Vandetanib—Asthenia—Methotrexate—ankylosing spondylitis	0.000192	0.000754	CcSEcCtD
Vandetanib—Nausea—Prednisone—ankylosing spondylitis	0.00019	0.000746	CcSEcCtD
Vandetanib—Pruritus—Methotrexate—ankylosing spondylitis	0.000189	0.000743	CcSEcCtD
Vandetanib—Diarrhoea—Methotrexate—ankylosing spondylitis	0.000183	0.000719	CcSEcCtD
Vandetanib—Dizziness—Methotrexate—ankylosing spondylitis	0.000177	0.000694	CcSEcCtD
Vandetanib—Vomiting—Methotrexate—ankylosing spondylitis	0.00017	0.000668	CcSEcCtD
Vandetanib—Rash—Methotrexate—ankylosing spondylitis	0.000169	0.000662	CcSEcCtD
Vandetanib—Dermatitis—Methotrexate—ankylosing spondylitis	0.000169	0.000662	CcSEcCtD
Vandetanib—Headache—Methotrexate—ankylosing spondylitis	0.000168	0.000658	CcSEcCtD
Vandetanib—Nausea—Methotrexate—ankylosing spondylitis	0.000159	0.000624	CcSEcCtD
Vandetanib—LCK—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.00015	0.000525	CbGpPWpGaD
Vandetanib—EGFR—Immune System—ERAP1—ankylosing spondylitis	0.000149	0.000524	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—CD79A—ankylosing spondylitis	0.000147	0.000517	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—HLA-C—ankylosing spondylitis	0.000147	0.000516	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—MMP3—ankylosing spondylitis	0.000147	0.000514	CbGpPWpGaD
Vandetanib—BLK—Immune System—IL1RN—ankylosing spondylitis	0.000146	0.000512	CbGpPWpGaD
Vandetanib—FGR—Immune System—IL1RN—ankylosing spondylitis	0.000145	0.00051	CbGpPWpGaD
Vandetanib—FGR—Innate Immune System—TLR4—ankylosing spondylitis	0.000144	0.000506	CbGpPWpGaD
Vandetanib—LCK—Immune System—ERAP1—ankylosing spondylitis	0.000144	0.000505	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—HLA-C—ankylosing spondylitis	0.000142	0.000498	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000141	0.000496	CbGpPWpGaD
Vandetanib—ALB—Vitamin B12 Metabolism—TNF—ankylosing spondylitis	0.00014	0.00049	CbGpPWpGaD
Vandetanib—ERBB3—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000139	0.000488	CbGpPWpGaD
Vandetanib—LCK—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000139	0.000486	CbGpPWpGaD
Vandetanib—YES1—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000139	0.000486	CbGpPWpGaD
Vandetanib—ERBB3—Innate Immune System—CRP—ankylosing spondylitis	0.000138	0.000485	CbGpPWpGaD
Vandetanib—VEGFA—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.000138	0.000483	CbGpPWpGaD
Vandetanib—YES1—Innate Immune System—HLA-B—ankylosing spondylitis	0.000137	0.000482	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CARD9—ankylosing spondylitis	0.000136	0.000479	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000136	0.000478	CbGpPWpGaD
Vandetanib—YES1—Immune System—HLA-C—ankylosing spondylitis	0.000135	0.000474	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL1R2—ankylosing spondylitis	0.000134	0.000471	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—MMP3—ankylosing spondylitis	0.000134	0.00047	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—IL1RN—ankylosing spondylitis	0.000134	0.000469	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—CD79A—ankylosing spondylitis	0.000133	0.000467	CbGpPWpGaD
Vandetanib—ERBB3—Innate Immune System—TLR4—ankylosing spondylitis	0.000132	0.000465	CbGpPWpGaD
Vandetanib—YES1—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000132	0.000462	CbGpPWpGaD
Vandetanib—LCK—Immune System—CARD9—ankylosing spondylitis	0.000132	0.000462	CbGpPWpGaD
Vandetanib—MKNK1—Disease—HLA-A—ankylosing spondylitis	0.000131	0.000461	CbGpPWpGaD
Vandetanib—EPHA5—Developmental Biology—TNF—ankylosing spondylitis	0.000131	0.000459	CbGpPWpGaD
Vandetanib—ABL2—Developmental Biology—TNF—ankylosing spondylitis	0.000131	0.000459	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000129	0.000454	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—B3GNT2—ankylosing spondylitis	0.000129	0.000452	CbGpPWpGaD
Vandetanib—BLK—Immune System—CD79A—ankylosing spondylitis	0.000128	0.00045	CbGpPWpGaD
Vandetanib—FGR—Immune System—CD79A—ankylosing spondylitis	0.000128	0.000448	CbGpPWpGaD
Vandetanib—SRC—Immune System—ERAP1—ankylosing spondylitis	0.000127	0.000447	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000127	0.000445	CbGpPWpGaD
Vandetanib—EPHA8—Developmental Biology—TNF—ankylosing spondylitis	0.000126	0.000442	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—HLA-C—ankylosing spondylitis	0.000126	0.000441	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000125	0.000438	CbGpPWpGaD
Vandetanib—FYN—Disease—B3GNT2—ankylosing spondylitis	0.000124	0.000435	CbGpPWpGaD
Vandetanib—EGFR—Spinal Cord Injury—TNF—ankylosing spondylitis	0.000124	0.000435	CbGpPWpGaD
Vandetanib—YES1—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000122	0.000428	CbGpPWpGaD
Vandetanib—YES1—Innate Immune System—CRP—ankylosing spondylitis	0.000121	0.000426	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—IL1A—ankylosing spondylitis	0.000121	0.000424	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000121	0.000423	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—CD40LG—ankylosing spondylitis	0.00012	0.000421	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—CD79A—ankylosing spondylitis	0.000117	0.000412	CbGpPWpGaD
Vandetanib—YES1—Immune System—IL1RN—ankylosing spondylitis	0.000117	0.000412	CbGpPWpGaD
Vandetanib—EPHB6—Developmental Biology—TNF—ankylosing spondylitis	0.000117	0.000411	CbGpPWpGaD
Vandetanib—SRC—Immune System—CARD9—ankylosing spondylitis	0.000116	0.000409	CbGpPWpGaD
Vandetanib—YES1—Innate Immune System—TLR4—ankylosing spondylitis	0.000116	0.000408	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—HLA-B—ankylosing spondylitis	0.000114	0.000401	CbGpPWpGaD
Vandetanib—ABCC1—Disease—B3GNT2—ankylosing spondylitis	0.000114	0.000399	CbGpPWpGaD
Vandetanib—ALB—Folate Metabolism—TNF—ankylosing spondylitis	0.000114	0.000399	CbGpPWpGaD
Vandetanib—PDGFRB—MAPK Signaling Pathway—TNF—ankylosing spondylitis	0.000112	0.000394	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—MMP3—ankylosing spondylitis	0.000111	0.00039	CbGpPWpGaD
Vandetanib—EPHA6—Developmental Biology—TNF—ankylosing spondylitis	0.00011	0.000387	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—IL1A—ankylosing spondylitis	0.000109	0.000383	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—CD40LG—ankylosing spondylitis	0.000109	0.000381	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000108	0.000378	CbGpPWpGaD
Vandetanib—EGFR—Disease—B3GNT2—ankylosing spondylitis	0.000107	0.000376	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—HLA-A—ankylosing spondylitis	0.000106	0.000371	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000105	0.00037	CbGpPWpGaD
Vandetanib—BLK—Immune System—IL1A—ankylosing spondylitis	0.000105	0.000369	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000105	0.000368	CbGpPWpGaD
Vandetanib—FGR—Immune System—IL1A—ankylosing spondylitis	0.000105	0.000367	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—HLA-B—ankylosing spondylitis	0.000104	0.000367	CbGpPWpGaD
Vandetanib—BLK—Immune System—CD40LG—ankylosing spondylitis	0.000104	0.000367	CbGpPWpGaD
Vandetanib—FGR—Immune System—CD40LG—ankylosing spondylitis	0.000104	0.000365	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000104	0.000364	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000103	0.000362	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—HLA-B—ankylosing spondylitis	0.000103	0.000362	CbGpPWpGaD
Vandetanib—LCK—Disease—B3GNT2—ankylosing spondylitis	0.000103	0.000362	CbGpPWpGaD
Vandetanib—YES1—Immune System—CD79A—ankylosing spondylitis	0.000103	0.000362	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HLA-C—ankylosing spondylitis	0.000103	0.000361	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—HLA-B—ankylosing spondylitis	0.000102	0.000359	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—HLA-B—ankylosing spondylitis	0.000102	0.000357	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000102	0.000357	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—CRP—ankylosing spondylitis	0.000101	0.000354	CbGpPWpGaD
Vandetanib—LYN—Immune System—HLA-C—ankylosing spondylitis	0.000101	0.000354	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—HLA-B—ankylosing spondylitis	0.000101	0.000354	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.0001	0.000352	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HLA-C—ankylosing spondylitis	0.0001	0.000352	CbGpPWpGaD
Vandetanib—BLK—Immune System—HLA-B—ankylosing spondylitis	9.93e-05	0.000349	CbGpPWpGaD
Vandetanib—FYN—Immune System—HLA-C—ankylosing spondylitis	9.92e-05	0.000348	CbGpPWpGaD
Vandetanib—FGR—Immune System—HLA-B—ankylosing spondylitis	9.9e-05	0.000347	CbGpPWpGaD
Vandetanib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	9.87e-05	0.000346	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—HLA-B—ankylosing spondylitis	9.82e-05	0.000345	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—TLR4—ankylosing spondylitis	9.68e-05	0.00034	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—HLA-B—ankylosing spondylitis	9.67e-05	0.000339	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—IL1A—ankylosing spondylitis	9.63e-05	0.000338	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—PTGER4—ankylosing spondylitis	9.59e-05	0.000337	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—CD40LG—ankylosing spondylitis	9.57e-05	0.000336	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—HLA-A—ankylosing spondylitis	9.57e-05	0.000336	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—B3GNT2—ankylosing spondylitis	9.52e-05	0.000334	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—PTGER4—ankylosing spondylitis	9.35e-05	0.000328	CbGpPWpGaD
Vandetanib—EGFR—MAPK Signaling Pathway—TNF—ankylosing spondylitis	9.34e-05	0.000328	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—HLA-A—ankylosing spondylitis	9.3e-05	0.000326	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—PTGER4—ankylosing spondylitis	9.24e-05	0.000324	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—CRP—ankylosing spondylitis	9.24e-05	0.000324	CbGpPWpGaD
Vandetanib—BLK—Immune System—HLA-A—ankylosing spondylitis	9.2e-05	0.000323	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—CD79A—ankylosing spondylitis	9.19e-05	0.000323	CbGpPWpGaD
Vandetanib—FGR—Immune System—HLA-A—ankylosing spondylitis	9.17e-05	0.000322	CbGpPWpGaD
Vandetanib—SRC—Disease—B3GNT2—ankylosing spondylitis	9.14e-05	0.000321	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—CRP—ankylosing spondylitis	9.13e-05	0.00032	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—HLA-B—ankylosing spondylitis	9.1e-05	0.00032	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—HLA-A—ankylosing spondylitis	9.1e-05	0.000319	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—CRP—ankylosing spondylitis	9.04e-05	0.000317	CbGpPWpGaD
Vandetanib—ALB—Selenium Micronutrient Network—TNF—ankylosing spondylitis	9.03e-05	0.000317	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—CRP—ankylosing spondylitis	9e-05	0.000316	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—HLA-A—ankylosing spondylitis	8.96e-05	0.000315	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL1RN—ankylosing spondylitis	8.94e-05	0.000314	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—CRP—ankylosing spondylitis	8.9e-05	0.000312	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—TLR4—ankylosing spondylitis	8.85e-05	0.000311	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—CD40LG—ankylosing spondylitis	8.78e-05	0.000308	CbGpPWpGaD
Vandetanib—BLK—Immune System—CRP—ankylosing spondylitis	8.78e-05	0.000308	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL1RN—ankylosing spondylitis	8.75e-05	0.000307	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—TLR4—ankylosing spondylitis	8.75e-05	0.000307	CbGpPWpGaD
Vandetanib—FGR—Immune System—CRP—ankylosing spondylitis	8.75e-05	0.000307	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL1RN—ankylosing spondylitis	8.71e-05	0.000306	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—PTGER4—ankylosing spondylitis	8.71e-05	0.000306	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—HLA-B—ankylosing spondylitis	8.7e-05	0.000305	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—TLR4—ankylosing spondylitis	8.67e-05	0.000304	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—TLR4—ankylosing spondylitis	8.63e-05	0.000303	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL1RN—ankylosing spondylitis	8.62e-05	0.000302	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HLA-C—ankylosing spondylitis	8.57e-05	0.000301	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—TLR4—ankylosing spondylitis	8.54e-05	0.0003	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—CD40LG—ankylosing spondylitis	8.47e-05	0.000297	CbGpPWpGaD
Vandetanib—YES1—Immune System—IL1A—ankylosing spondylitis	8.45e-05	0.000297	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—HLA-A—ankylosing spondylitis	8.43e-05	0.000296	CbGpPWpGaD
Vandetanib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	8.43e-05	0.000296	CbGpPWpGaD
Vandetanib—BLK—Immune System—TLR4—ankylosing spondylitis	8.42e-05	0.000295	CbGpPWpGaD
Vandetanib—YES1—Immune System—CD40LG—ankylosing spondylitis	8.4e-05	0.000295	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—PTGER4—ankylosing spondylitis	8.4e-05	0.000295	CbGpPWpGaD
Vandetanib—FGR—Immune System—TLR4—ankylosing spondylitis	8.39e-05	0.000294	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—HLA-B—ankylosing spondylitis	8.39e-05	0.000294	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—B3GNT2—ankylosing spondylitis	8.38e-05	0.000294	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—HLA-B—ankylosing spondylitis	8.36e-05	0.000293	CbGpPWpGaD
Vandetanib—LCK—Immune System—HLA-C—ankylosing spondylitis	8.26e-05	0.00029	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—PTGER4—ankylosing spondylitis	8.11e-05	0.000285	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—HLA-B—ankylosing spondylitis	8.05e-05	0.000283	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—CRP—ankylosing spondylitis	8.05e-05	0.000282	CbGpPWpGaD
Vandetanib—YES1—Immune System—HLA-B—ankylosing spondylitis	7.99e-05	0.00028	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CD79A—ankylosing spondylitis	7.85e-05	0.000275	CbGpPWpGaD
Vandetanib—ERBB3—Disease—HLA-A—ankylosing spondylitis	7.79e-05	0.000273	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—HLA-A—ankylosing spondylitis	7.74e-05	0.000272	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—TLR4—ankylosing spondylitis	7.71e-05	0.000271	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—CRP—ankylosing spondylitis	7.69e-05	0.00027	CbGpPWpGaD
Vandetanib—LYN—Immune System—CD79A—ankylosing spondylitis	7.68e-05	0.00027	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CD79A—ankylosing spondylitis	7.65e-05	0.000268	CbGpPWpGaD
Vandetanib—FYN—Immune System—CD79A—ankylosing spondylitis	7.57e-05	0.000266	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—CD40LG—ankylosing spondylitis	7.49e-05	0.000263	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—MMP3—ankylosing spondylitis	7.47e-05	0.000262	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—HLA-A—ankylosing spondylitis	7.46e-05	0.000262	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL1RN—ankylosing spondylitis	7.44e-05	0.000261	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—HLA-B—ankylosing spondylitis	7.42e-05	0.000261	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—CRP—ankylosing spondylitis	7.41e-05	0.00026	CbGpPWpGaD
Vandetanib—YES1—Immune System—HLA-A—ankylosing spondylitis	7.4e-05	0.00026	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—TLR4—ankylosing spondylitis	7.37e-05	0.000259	CbGpPWpGaD
Vandetanib—SRC—Immune System—HLA-C—ankylosing spondylitis	7.31e-05	0.000257	CbGpPWpGaD
Vandetanib—SRC—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	7.19e-05	0.000252	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL1RN—ankylosing spondylitis	7.17e-05	0.000252	CbGpPWpGaD
Vandetanib—KDR—Developmental Biology—TNF—ankylosing spondylitis	7.16e-05	0.000251	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—HLA-B—ankylosing spondylitis	7.13e-05	0.00025	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—TLR4—ankylosing spondylitis	7.11e-05	0.000249	CbGpPWpGaD
Vandetanib—YES1—Immune System—CRP—ankylosing spondylitis	7.06e-05	0.000248	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—MMP3—ankylosing spondylitis	6.83e-05	0.00024	CbGpPWpGaD
Vandetanib—YES1—Immune System—TLR4—ankylosing spondylitis	6.77e-05	0.000238	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—MMP3—ankylosing spondylitis	6.65e-05	0.000234	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—HLA-A—ankylosing spondylitis	6.6e-05	0.000232	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—MMP3—ankylosing spondylitis	6.58e-05	0.000231	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—CRP—ankylosing spondylitis	6.56e-05	0.00023	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CD79A—ankylosing spondylitis	6.54e-05	0.000229	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL1A—ankylosing spondylitis	6.44e-05	0.000226	CbGpPWpGaD
Vandetanib—VEGFA—Developmental Biology—TNF—ankylosing spondylitis	6.44e-05	0.000226	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CD40LG—ankylosing spondylitis	6.4e-05	0.000225	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL1RN—ankylosing spondylitis	6.35e-05	0.000223	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL1A—ankylosing spondylitis	6.3e-05	0.000221	CbGpPWpGaD
Vandetanib—LCK—Immune System—CD79A—ankylosing spondylitis	6.3e-05	0.000221	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—TLR4—ankylosing spondylitis	6.29e-05	0.000221	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL1A—ankylosing spondylitis	6.27e-05	0.00022	CbGpPWpGaD
Vandetanib—LYN—Immune System—CD40LG—ankylosing spondylitis	6.26e-05	0.00022	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CD40LG—ankylosing spondylitis	6.24e-05	0.000219	CbGpPWpGaD
Vandetanib—YES1—Developmental Biology—TNF—ankylosing spondylitis	6.22e-05	0.000218	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL1A—ankylosing spondylitis	6.2e-05	0.000218	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—MMP3—ankylosing spondylitis	6.2e-05	0.000218	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PTGER4—ankylosing spondylitis	6.18e-05	0.000217	CbGpPWpGaD
Vandetanib—FYN—Immune System—CD40LG—ankylosing spondylitis	6.17e-05	0.000216	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HLA-B—ankylosing spondylitis	6.09e-05	0.000214	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PTGER4—ankylosing spondylitis	6.05e-05	0.000212	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MMP3—ankylosing spondylitis	5.98e-05	0.00021	CbGpPWpGaD
Vandetanib—LYN—Immune System—HLA-B—ankylosing spondylitis	5.96e-05	0.000209	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PTGER4—ankylosing spondylitis	5.96e-05	0.000209	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HLA-B—ankylosing spondylitis	5.93e-05	0.000208	CbGpPWpGaD
Vandetanib—FYN—Immune System—HLA-B—ankylosing spondylitis	5.87e-05	0.000206	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MMP3—ankylosing spondylitis	5.78e-05	0.000203	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HLA-A—ankylosing spondylitis	5.64e-05	0.000198	CbGpPWpGaD
Vandetanib—SRC—Immune System—CD79A—ankylosing spondylitis	5.58e-05	0.000196	CbGpPWpGaD
Vandetanib—LYN—Immune System—HLA-A—ankylosing spondylitis	5.52e-05	0.000194	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HLA-A—ankylosing spondylitis	5.5e-05	0.000193	CbGpPWpGaD
Vandetanib—FYN—Immune System—HLA-A—ankylosing spondylitis	5.44e-05	0.000191	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CRP—ankylosing spondylitis	5.38e-05	0.000189	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL1A—ankylosing spondylitis	5.36e-05	0.000188	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CD40LG—ankylosing spondylitis	5.33e-05	0.000187	CbGpPWpGaD
Vandetanib—LYN—Immune System—CRP—ankylosing spondylitis	5.27e-05	0.000185	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CRP—ankylosing spondylitis	5.24e-05	0.000184	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—HLA-A—ankylosing spondylitis	5.21e-05	0.000183	CbGpPWpGaD
Vandetanib—FYN—Immune System—CRP—ankylosing spondylitis	5.19e-05	0.000182	CbGpPWpGaD
Vandetanib—ALB—Metabolism—B3GNT2—ankylosing spondylitis	5.17e-05	0.000181	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL1A—ankylosing spondylitis	5.16e-05	0.000181	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—TLR4—ankylosing spondylitis	5.16e-05	0.000181	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PTGER4—ankylosing spondylitis	5.15e-05	0.000181	CbGpPWpGaD
Vandetanib—LCK—Immune System—CD40LG—ankylosing spondylitis	5.13e-05	0.00018	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HLA-B—ankylosing spondylitis	5.07e-05	0.000178	CbGpPWpGaD
Vandetanib—LYN—Immune System—TLR4—ankylosing spondylitis	5.05e-05	0.000177	CbGpPWpGaD
Vandetanib—ABL1—Immune System—TLR4—ankylosing spondylitis	5.03e-05	0.000176	CbGpPWpGaD
Vandetanib—FYN—Disease—HLA-A—ankylosing spondylitis	5.02e-05	0.000176	CbGpPWpGaD
Vandetanib—FYN—Immune System—TLR4—ankylosing spondylitis	4.97e-05	0.000174	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PTGER4—ankylosing spondylitis	4.96e-05	0.000174	CbGpPWpGaD
Vandetanib—LCK—Immune System—HLA-B—ankylosing spondylitis	4.88e-05	0.000171	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HLA-A—ankylosing spondylitis	4.7e-05	0.000165	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—TNF—ankylosing spondylitis	4.64e-05	0.000163	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—TNF—ankylosing spondylitis	4.61e-05	0.000162	CbGpPWpGaD
Vandetanib—ABCC1—Disease—HLA-A—ankylosing spondylitis	4.6e-05	0.000161	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL1A—ankylosing spondylitis	4.57e-05	0.00016	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—TNF—ankylosing spondylitis	4.56e-05	0.00016	CbGpPWpGaD
Vandetanib—SRC—Immune System—CD40LG—ankylosing spondylitis	4.55e-05	0.00016	CbGpPWpGaD
Vandetanib—LCK—Immune System—HLA-A—ankylosing spondylitis	4.53e-05	0.000159	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CRP—ankylosing spondylitis	4.48e-05	0.000157	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MMP3—ankylosing spondylitis	4.4e-05	0.000154	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PTGER4—ankylosing spondylitis	4.39e-05	0.000154	CbGpPWpGaD
Vandetanib—EGFR—Disease—HLA-A—ankylosing spondylitis	4.34e-05	0.000152	CbGpPWpGaD
Vandetanib—SRC—Immune System—HLA-B—ankylosing spondylitis	4.32e-05	0.000152	CbGpPWpGaD
Vandetanib—LCK—Immune System—CRP—ankylosing spondylitis	4.32e-05	0.000152	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MMP3—ankylosing spondylitis	4.31e-05	0.000151	CbGpPWpGaD
Vandetanib—EGFR—Immune System—TLR4—ankylosing spondylitis	4.29e-05	0.000151	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MMP3—ankylosing spondylitis	4.24e-05	0.000149	CbGpPWpGaD
Vandetanib—LCK—Disease—HLA-A—ankylosing spondylitis	4.18e-05	0.000147	CbGpPWpGaD
Vandetanib—LCK—Immune System—TLR4—ankylosing spondylitis	4.14e-05	0.000145	CbGpPWpGaD
Vandetanib—SRC—Immune System—HLA-A—ankylosing spondylitis	4.01e-05	0.000141	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—TNF—ankylosing spondylitis	3.94e-05	0.000138	CbGpPWpGaD
Vandetanib—SRC—Immune System—CRP—ankylosing spondylitis	3.82e-05	0.000134	CbGpPWpGaD
Vandetanib—SRC—Disease—HLA-A—ankylosing spondylitis	3.7e-05	0.00013	CbGpPWpGaD
Vandetanib—SRC—Immune System—TLR4—ankylosing spondylitis	3.66e-05	0.000129	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MMP3—ankylosing spondylitis	3.66e-05	0.000129	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MMP3—ankylosing spondylitis	3.53e-05	0.000124	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—TNF—ankylosing spondylitis	3.36e-05	0.000118	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MMP3—ankylosing spondylitis	3.13e-05	0.00011	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	2.79e-05	9.79e-05	CbGpPWpGaD
